Plasma total and nervous system derived exosomal (NDE) α-synuclein have been determined as potential biomarkers of Parkinson's disease (PD). To explore the utility of plasma α-synuclein in the prodromal phase of PD, plasma total and NDE α-synuclein were evaluated in baseline and 2-year follow-up samples from 256 individuals recruited as part of the Parkinson's Associated Risk Syndrome (PARS) study. The results demonstrated that baseline and longitudinal increases in total α-synuclein predicted progression of cognitive decline in hyposmic individuals with dopamine transporter (DAT) binding reduction. On the other hand, a longitudinal decrease in NDE α-synuclein predicted worsening cognitive scores in hyposmic individuals with DAT binding reduction. Finally, in individuals with faster DAT progression, decreasing NDE/total α-synuclein ratio was associated with a larger reduction in DAT from baseline to follow-up. These results suggest that, though underlying mechanisms remain to be defined, alterations in plasma total and NDE α-synuclein concentrations are likely associated with PD progression, especially in the aspect of cognitive impairment, at early stages of the disease.
Introduction
Parkinson's disease (PD), a progressive neurodegenerative disease, has a prodromal phase, which precedes the onset of classic parkinsonism (de Lau and Breteler, 2006; Gonera et al., 1997) . Development of novel tools to evaluate disease progression at the prodromal stage, which can include motor or nonmotor symptoms, could benefit patients, particularly in the use of potential disease-modifying interventions that would likely be most efficacious when started in the earliest stages of the disease (Athauda and Foltynie, 2015) . Clinically, a sense of smell that is impaired (hyposmia) or absent (anosmia) could be a useful marker of premotor PD, as significant loss of olfactory function has been reported in PD patients and the extent of smell loss is independent of disease duration, disease stage or medication (Doty et al., 1988) .
However, the loss of olfactory function is neither sensitive nor specific enough to be used as a sole biomarker for PD, as a subset of PD patients do not suffer from loss of olfactory function, and it can also occur in other settings such as brain trauma and Alzheimer's disease (AD). Thus, the utility of hyposmia/anosmia as a biomarker might be improved when used in combination with additional specific imaging or biochemical biomarkers.
Although dopamine transporter (DAT) imaging reveals nigrostriatal dopaminergic dysfunction, like many imaging based screening tests, it is associated with a number of limitations, making the development of a more convenient biochemical or molecular marker in body fluids attractive. Among the candidate biomarkers that have been tested, α-synuclein (α-syn) is considered the most promising, based on its status as the primary component of Lewy bodies and its implication in the https://doi.org/10.1016/j.nbd.2018.04.015 Received 4 January 2018; Received in revised form 9 April 2018; Accepted 23 April 2018
